Influenza A virus neuraminidase N2 (NA) (NA)

Influenza A N2 neuraminidase is a major surface glycoprotein and essential enzyme found on the envelope of influenza A virus subtypes, such as H3N2 and H2N2 (NIH, Wikipedia). It functions as a sialidase (EC 3.2.1.18), catalyzing the cleavage of terminal sialic acid residues from host cell receptors and viral glycoproteins (Britannica, PubChem). This enzymatic activity is critical for the release of newly formed virions from the surface of infected cells, preventing their aggregation and allowing the virus to spread throughout the respiratory tract (Wikipedia). Additionally, N2 neuraminidase facilitates viral movement through the respiratory mucus by degrading sialic acid-containing mucins (NIH). As a primary therapeutic target, it is inhibited by drugs such as oseltamivir, zanamivir, and peramivir, which block the enzyme's active site and arrest the viral life cycle (NIH). However, the protein is subject to frequent antigenic drift and the emergence of drug-resistant mutations, such as R292K and E119V, which can compromise the efficacy of existing treatments (NIH, ProQuest). Understanding the structural and functional characteristics of N2 neuraminidase is vital for the development of next-generation antivirals and more effective seasonal vaccines (MDPI, TalkMed).

Other names

SialidaseExo-alpha-sialidaseN-acetylneuraminate glycohydrolaseReceptor-destroying enzyme

Neuraminidase inhibitors (NAIs) act as transition-state analogues that competitively bind to the highly conserved active site of the neuraminidase enzyme (YouTube, Wikipedia). By inhibiting the cleavage of terminal sialic acid residues from host cell receptors and viral glycoproteins, these drugs prevent the release of progeny virions from the infected cell surface, thereby limiting the spread of the infection to adjacent cells (NIH, Britannica).